Champions Oncology (CSBR) Operating Leases (2019 - 2026)
Champions Oncology (CSBR) posted quarterly Operating Leases of $4.5 million for Q2 2026, down 2.63% year-over-year from $4.6 million in Q2 2025, and down 7.81% quarter-over-quarter from $4.9 million in Q1 2026.
Champions Oncology (CSBR) Operating Leases (2019 - 2026) Analysis & Trends
Champions Oncology's Operating Leases history runs 8 years deep, the most recent figure standing at $4.5 million for Q2 2026.
- In Q2 2026, Operating Leases fell 2.63% year-over-year to $4.5 million; the TTM figure through Apr 2026 stood at $4.5 million (down 2.63% YoY), while the FY2026 annual figure was $4.5 million, down 2.63% from the prior year.
- Operating Leases for Q2 2026 stood at $4.5 million, down from $4.9 million in the prior quarter.
- The five-year high for Operating Leases was $9.2 million in Q3 2022, with the low at $4.5 million in Q2 2026.
- The 5-year median for Operating Leases is $7.2 million (2023), against an average of $7.1 million.
- The sharpest annual moves came in 2022 and 2026: Operating Leases jumped 48.64% in 2022, then decreased 23.97% in 2026.
- Champions Oncology's Operating Leases stood at $9.0 million in 2022, then slipped by 10.21% to $8.0 million in 2023, then slipped by 15.84% to $6.8 million in 2024, then retreated by 22.23% to $5.3 million in 2025, then declined by 14.37% to $4.5 million in 2026.
- Business Quant data shows CSBR's Operating Leases at $4.5 million in Q2 2026, $4.9 million in Q1 2026, and $5.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.51 Mn |
| Jan 31, 2026 | 4.89 Mn |
| Oct 31, 2025 | 5.27 Mn |
| Jul 31, 2025 | 5.75 Mn |
| Apr 30, 2025 | 4.63 Mn |
| Jan 31, 2025 | 6.44 Mn |
| Oct 31, 2024 | 6.78 Mn |
| Jul 31, 2024 | 7.11 Mn |
| Apr 30, 2024 | 6.09 Mn |
| Jan 31, 2024 | 7.74 Mn |
| Oct 31, 2023 | 8.05 Mn |
| Jul 31, 2023 | 8.35 Mn |
| Apr 30, 2023 | 7.39 Mn |
| Jan 31, 2023 | 8.87 Mn |
| Oct 31, 2022 | 8.97 Mn |
| Jul 31, 2022 | 9.23 Mn |
| Apr 30, 2022 | 8.41 Mn |
| Jan 31, 2022 | 8.62 Mn |
| Oct 31, 2021 | 8.53 Mn |
| Jul 31, 2021 | 8.65 Mn |